date,text,url,form,accepted_time
2020-07-22," 8-k 1 nc10013644x1_8k.htm form 8-k united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or section 15(d) of the securities exchange act of 1934 date of report (date of earliest event reported): july 22, 2020 arya sciences acquisition corp ii (exact name of registrant as specified in its charter) cayman islands (state or other jurisdiction of incorporation or organization) 001-39311 (commission file number) 98-1533670 (irs employer identification number) 51 astor place, 10th floor new york, ny 10003 (address of principal executive offices) (212) 284-2300 registrant’s telephone number, including area code not applicable (former name or former address, if changed since last report) check the appropriate box below if the form 8-k filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions: ☐ written communications pursuant to rule 425 under the securities act (17 cfr 230.425) ☐ soliciting material pursuant to rule 14a-12 under the exchange act (17 cfr 240.14a-12) ☐ pre-commencement communications pursuant to rule 14d-2(b) under the exchange act (17 cfr 240.14d-2(b)) ☐ pre-commencement communications pursuant to rule 13e-4(c) under the exchange act (17 cfr 240.13e-4(c)) securities registered pursuant to section 12(b) of the act: title of each class trading symbol(s) name of each exchange on which registered units, each consisting of one class a ordinary share, $0.0001 par value, and one-third of one redeemable warrant arybu the nasdaq capital market class a ordinary shares included as part of the units aryb the nasdaq capital market redeemable warrants included as part of the units, each whole warrant exercisable for one class a ordinary share at an exercise price of $11.50 arybw the nasdaq capital market indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the securities act of 1933 or rule 12b-2 of the securities exchange act of 1934. emerging growth company ☒ if an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the exchange act. ☐ item 8.01. other events. on july 22, 2020, arya sciences acquisition corp ii (the “company”) announced that the holders of the company’s units (the “units”) may elect to separately trade the class a ordinary shares, par value $0.0001 per share (“class a ordinary shares”), and redeemable warrants included in the units commencing on july 24, 2020. each unit consists of one class a ordinary share and one-third of one redeemable warrant to purchase one class a ordinary share. any units not separated will continue to trade on the the nasdaq capital market (“nasdaq”) under the symbol “arybu”. any underlying class a ordinary shares and warrants that are separated will trade on nasdaq under the symbols “aryb” and “arybw,” respectively. no fractional warrants will be issued upon separation of the units and only whole warrants will trade. holders of units will need to have their brokers contact continental stock transfer & trust company, the company’s transfer agent, in order to separate the holders’ units into class a ordinary shares and warrants. a copy of the press release issued by the company announcing the separate trading of the securities underlying the units is attached hereto as exhibit 99.1. item 9.01. financial statements and exhibits. (d) exhibits. exhibit no. description 99.1 press release, dated july 22, 2020. signature pursuant to the requirements of the securities exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. dated: july 22, 2020 arya sciences acquisition corp ii by: /s/ adam stone name: adam stone title: chief executive officer ",https://www.sec.gov/Archives/edgar/data/1805387/000114036120016538/0001140361-20-016538-index.htm,8-K,2020-07-22 16:44:00
2020-06-15," 8-k 1 nc10012774x1_8k.htm form 8-k united states securities and exchange commission washington, dc 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of report (date of earliest event reported): june 9, 2020 arya sciences acquisition corp ii (exact name of registrant as specified in its charter) cayman islands (state or other jurisdiction of incorporation or organization) 001-39311 (commission file number) 98-1533670 (irs employer identification no.) 51 astor place, 10th floor new york, ny (address of principal executive offices) 10003 (zip code) (212) 284-2300 registrant’s telephone number, including area code not applicable (former name or former address, if changed since last report) check the appropriate box below if the form 8-k filing is intended to simultaneously satisfy the filing obligation of the registrant under anyof the following provisions: ☐ written communications pursuant to rule 425 under the securities act (17 cfr 230.425) ☐ soliciting material pursuant to rule 14a-12 under the exchange act (17 cfr 240.14a-12) ☐ pre-commencement communications pursuant to rule 14d-2(b) under the exchange act (17 cfr 240.14d-2(b)) ☐ pre-commencement communications pursuant to rule 13e-4(c) under the exchange act (17 cfr 240.13e-4(c)) securities registered pursuant to section 12(b) of the act: title of each class trading symbol(s) name of each exchange on which registered units, each consisting of one class a ordinary share, $0.0001 par value, and one-third of one redeemable warrant arybu the nasdaq capital market class a ordinary shares included as part of the units aryb the nasdaq capital market redeemable warrants included as part of the units, each whole warrant exercisable for one class a ordinary share at an exercise price of $11.50 arybw the nasdaq capital market indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the securities act of 1933 or rule 12b-2 of the securities exchange act of 1934. emerging growth company ☒ if an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the exchange act. ☐ item 8.01. entry into a material definitive agreement. on june 9, 2020, arya sciences acquisition corp ii (the “company”) consummated an initial public offering (the “ipo”) of 14,950,000 units (the “units”), including the 1,950,000 units as a result of the underwriters’ full exercise of their over-allotment option, at an offering price of $10.00 per unit and a private placement with arya sciences holdings ii of 499,000 private placement units, each private placement unit consisting of one class a ordinary share and one-third of one redeemable warrant, each whole warrant exercisable to purchase one class a ordinary share at $11.50 per share, subject to adjustment, at a price of $10.00 per private placement unit (the “private placement”). the net proceeds from the ipo, together with certain of the proceeds from the private placement, $149,500,000 in the aggregate (the “offering proceeds”), were placed in a trust account established for the benefit of the company’s public shareholders and the underwriters of the ipo with continental stock transfer & trust company acting as trustee. except with respect to interest earned on the offering proceeds held in the trust account that may be released to the company to pay its income taxes, if any, the company’s amended and restated memorandum and articles of association will provide that the offering proceeds will not be released from the trust account (1) to the company, until the completion of its initial business combination, or (2) to its public shareholders, until the earliest of (a) the completion of the its initial business combination, and then only in connection with those class a ordinary shares that such shareholders properly elected to redeem, subject to certain limitations, (b) the redemption of any public shares properly tendered in connection with a shareholder vote to amend the company’s amended and restated memorandum and articles of association (a) to modify the substance or timing of the company’s obligation to provide holders of its class a ordinary shares the right to have their shares redeemed in connection with the company’s initial business combination or to redeem 100% of its public shares if the company does not complete its initial business combination within 24 months from the closing of the ipo or (b) with respect to any other provision relating to the rights of holders of its class a ordinary shares, and (c) the redemption of the public shares if the company has not consummated its business combination within 24 months from the closing of the ipo, subject to applicable law. an audited balance sheet as of june 9, 2020 reflecting receipt of the offering proceeds has been issued by the company and is included as exhibit 99.1 to this current report on form 8-k. item 9.01. financial statements and exhibits. (d) exhibits 99.1 audited balance sheet signature pursuant to the requirements of the securities exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. dated: june 15, 2020 arya sciences acquisition corp ii by: /s/ adam stone name: adam stone title: chief executive officer ",https://www.sec.gov/Archives/edgar/data/1805387/000114036120013787/0001140361-20-013787-index.htm,8-K,2020-06-15 16:55:21
2020-06-09," 8-k 1 nt10009663x11_8k.htm form 8k united states securities and exchange commission washington, dc 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of report (date of earliest event reported): june 9, 2020 arya sciences acquisition corp ii (exact name of registrant as specified in its charter) cayman islands 001-39311 98-1533670 (state or other jurisdiction (commission (irs employer of incorporation or organization) file number) identification no.) 51 astor place, 10th floor new york, ny 10003 (address of principal executive offices) (zip code) (212) 284-2300 registrant’s telephone number, including area code not applicable (former name or former address, if changed since last report) check the appropriate box below if the form 8-k filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ written communications pursuant to rule 425 under the securities act (17 cfr 230.425) ☐ soliciting material pursuant to rule 14a-12 under the exchange act (17 cfr 240.14a-12) ☐ pre-commencement communications pursuant to rule 14d-2(b) under the exchange act (17 cfr 240.14d-2(b)) ☐ pre-commencement communications pursuant to rule 13e-4(c) under the exchange act (17 cfr 240.13e-4(c)) securities registered pursuant to section 12(b) of the act: trading name of each exchange on title of each class symbol(s) which registered units, each consisting of one class a ordinary share, $0.0001 par value, and one-third of one redeemable warrant arybu the nasdaq capital market class a ordinary shares included as part of the units aryb the nasdaq capital market redeemable warrants included as part of the units, each whole warrant exercisable for one class a ordinary share at an exercise price of $11.50 arybw the nasdaq capital market indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the securities act of 1933 or rule 12b-2 of the securities exchange act of 1934. emerging growth company ☒ if an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the exchange act. ☐ item 1.01. entry into a material definitive agreement. on june 4, 2020, the registration statement on form s-1 (file no. 333-238488) (the “registration statement”) relating to the initial public offering (the “ipo”) of arya sciences acquisition corp ii (the “company”) was declared effective by the u.s. securities and exchange commission, and the company subsequently filed, on june 4, 2020, a registration statement on form s-1 (file no. 333-238949) pursuant to rule 462(b) under the securities act of 1933, as amended, which was effective immediately upon filing. on june 9, 2020 the company consummated the ipo of 14,950,000 units (the “units”), which includes the exercise in full of the underwriters’ option to purchase an additional 1,950,000 units at the initial public offering price to cover over-allotments. each unit consists of one class a ordinary share, $0.0001 par value per share (the “class a ordinary shares”), and one-third of one redeemable warrant (the “public warrants”), each whole public warrant entitling the holder thereof to purchase one class a ordinary share at an exercise price of $11.50 per share, subject to adjustment. the units were sold at an offering price of $10.00 per unit, generating gross proceeds of $149,500,000. further, in connection with the ipo, the company entered into the following agreements, forms of which were previously filed as exhibits to the registration statement: • an underwriting agreement, dated june 4, 2020, among the company and jefferies llc and goldman sachs & co. llc, as representatives of the underwriters named in schedule a therein, which contains customary representations and warranties and indemnification of the underwriter by the company; • a private placement units purchase agreement, dated june 4, 2020, between the company and arya sciences holdings ii (the “sponsor”), pursuant to which the sponsor purchased 499,000 private placement units (the “private placement units”), each private placement unit consisting of one class a ordinary share and one-third of one redeemable warrant, each whole private placement warrant entitling the holder thereof to purchase one class a ordinary share at $11.50 per share, subject to adjustment (the “private placement warrants” and, together with the public warrants, the “warrants”), at a price of $10.00 per private placement unit; • a warrant agreement, dated june 9, 2020, between the company and continental stock transfer & trust company, as warrant agent (the “warrant agreement”), which sets forth the expiration and exercise price of and procedure for exercising the warrants; certain adjustment features of the terms of exercise; provisions relating to redemption and cashless exercise of the warrants; certain registration rights of the holders of warrants; provision for amendments to the warrant agreement; and indemnification of the warrant agent by the company under the agreement; • an investment management trust agreement, dated june 9, 2020, between the company and continental stock transfer & trust company, as trustee, which establishes the trust account that will hold the net proceeds of the ipo and certain of the proceeds of the sale of the private placement units, and sets forth the responsibilities of the trustee; the procedures for withdrawal and direction of funds from the trust account; and indemnification of the trustee by the company under the agreement; • a registration and shareholder rights agreement, dated june 9, 2020, among the company, the sponsor and certain equityholders of the company, which provides for customary demand and piggy-back registration rights for the sponsor, and customary piggy-back registration rights for such other equityholders, and, upon and following consummation of our initial business combination, the right of the sponsor to nominate three individuals for election to the company’s board of directors; • letter agreement, dated june 4, 2020, among the company, the sponsor and each executive officer and director of the company, pursuant to which each of the sponsor and each executive officer and director of the company has agreed to vote any class a ordinary shares held by him, her or it in favor of the company’s initial business combination; to facilitate the liquidation and winding up of the company if an initial business combination is not consummated within 24 months of the date hereof; to certain transfer restrictions with respect to the company’s securities; to certain indemnification obligations of the sponsor; and the company has agreed not to enter into a definitive agreement regarding an initial business combination without the prior consent of the sponsor; and • an administrative services agreement, dated june 9, 2020, between the company and the sponsor, pursuant to which the sponsor has agreed to make available office space, secretarial and administrative services, as may be required by the company from time to time, for $10,000 per month until the earlier of the company’s completion of its initial business combination or liquidation. the above descriptions are qualified in their entirety by reference to the full text of the applicable agreement, each of which is incorporated by reference herein and filed herewith as exhibits 1.1, 10.1, 4.1, 10.2, 10.3, 10.4 and 10.5, respectively. item 3.02. unregistered sales of equity securities. simultaneous with the consummation of the ipo and the issuance and sale of the units, the company consummated the private placement of 499,000 private placement units at a price of $10.00 per private placement unit, generating total proceeds of $4,990,000 (the “private placement”). the private placement warrants included in the private placement units purchased by the sponsor are substantially similar to the public warrants, except that if held by the sponsor or its permitted transferees, they (i) may be exercised for cash or on a cashless basis, (ii) are not subject to being called for redemption (except in certain circumstances when the public warrants are called for redemption and a certain price per class a ordinary share threshold is met) and (iii) subject to certain limited exceptions including the class a ordinary shares issuable upon exercise of the private placement warrants, will be subject to transfer restrictions until 30 days following the consummation of the company’s initial business combination. if the private placement warrants are held by holders other than the sponsor or its permitted transferees, the private placement warrants will be redeemable by the company in all redemption scenarios and exercisable by holders on the same basis as the public warrants. the private placement units have been issued pursuant to the private placement units purchase agreement and the private placement warrants have been issued pursuant to, and are governed by the warrant agreement. item 5.03. amendments to memorandum and articles of association. on june 4, 2020 and in connection with the ipo, the company adopted its amended and restated memorandum and articles of association. the amended and restated memorandum and articles of association is filed herewith as exhibit 3.1 and is incorporated by reference herein. item 9.01. financial statements and exhibits. (d) exhibits 1.1 underwriting agreement among the company, jefferies llc and goldman sachs & co. llc 3.1 amended and restated memorandum and articles of association 4.1 warrant agreement between continental stock transfer & trust company and the company 10.1 private placement units purchase agreement between the company and the sponsor 10.2 investment management trust agreement between continental stock transfer & trust company and the company 10.3 registration and shareholder rights agreement among the company, the sponsor and certain other equityholders named therein 10.4 letter agreement among the company, the sponsor and the company’s officers and directors 10.5 administrative services agreement between the company and the sponsor signature pursuant to the requirements of the securities exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. dated: june 9, 2020 arya sciences acquisition corp ii by: /s/ adam stone name: adam stone title: chief executive officer ",https://www.sec.gov/Archives/edgar/data/1805387/000114036120013438/0001140361-20-013438-index.htm,8-K,2020-06-09 17:15:42
